---
title: "CSPC says Innovation unit files new Hong Kong listing application after prior lapse"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290406575.md"
description: "CSPC Pharmaceutical Group announced that its subsidiary, CSPC Innovation, filed a new application for an H-share listing on the Hong Kong Stock Exchange on June 18, 2026. This follows the lapse of a previous filing. The offering details remain undecided, and completion depends on regulatory approvals from China's CSRC and Hong Kong authorities."
datetime: "2026-06-22T08:39:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290406575.md)
  - [en](https://longbridge.com/en/news/290406575.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290406575.md)
generator: "portal-rs"
---

# CSPC says Innovation unit files new Hong Kong listing application after prior lapse

-   CSPC Pharmaceutical Group updated markets on a proposed H-share listing of subsidiary CSPC Innovation. \* CSPC Innovation filed a fresh listing application with the Hong Kong Stock Exchange on June 18, 2026, following the lapse of a prior filing. \* CSPC expects CSPC Innovation to remain an indirect subsidiary if the listing completes. \* Offering size, structure, pricing, timetable remain undecided. \* Completion hinges on regulatory clearances, including China’s CSRC, Hong Kong’s Stock Exchange, and the SFC. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260622-12209989), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [300765.CN](https://longbridge.com/en/quote/300765.CN.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [CSPC Pharma wins China NMPA clearance to start Phase 1 trial of SYH2092 obesity drug](https://longbridge.com/en/news/297512143.md)
- [CSPC’s SYS6010 Wins Third Breakthrough Therapy Tag in High-Need Cancer Indications](https://longbridge.com/en/news/297638498.md)
- [CSPC Pharma says FDA grants Fast Track status to SYS6090 for MSS/pMMR metastatic colorectal cancer](https://longbridge.com/en/news/297024431.md)
- [CSPC says FDA clears RSV vaccine candidate SYS 6057 for US clinical trial](https://longbridge.com/en/news/296903628.md)
- [SFC flags Riverine China shareholding concentration, 92.42% held by small group](https://longbridge.com/en/news/297621165.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**